Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC

BACKGROUND: Greater than 50% of recurrences in estrogen receptor-positive (ER+) breast cancer occur after 5 years of adjuvant endocrine therapy. Biomarkers capable of improving the risk-benefit of extended adjuvant endocrine therapy for these late recurrences would be clinically valuable. We compare...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Sgroi, Dennis C., Sestak, Ivana, Cuzick, Jack, Zhang, Yi, Schnabel, Catherine A., Schroeder, Brock, Erlander, Mark G., Dunbier, Anita, Sidhu, Kally, Lopez-Knowles, Elena, Goss, Paul E., Dowsett, Mitch
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3918681/
https://ncbi.nlm.nih.gov/pubmed/24035531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70387-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg